Canopy Growth Corp.: Can Snoop Dogg Take it to New Highs?

Rap artist Snoop Dogg will roll out his Leafs by Snoop cannabis brand across the country later this month with the help of Canopy Growth Corp. (TSX:CGC), Canada’s largest marijuana producer. Is $10 in Canopy’s future?

| More on:
The Motley Fool

The partnership between Canopy Growth Corp. (TSX:CGC) and rapper Snoop Dogg’s Leafs by Snoop brand, first announced in February, is set to roll out three strains of Cannabis across Canada by the end of the month.

It’s a big a deal given the rapper’s huge following in the cannabis scene, but will it be enough to drive Canopy Growth stock to double digits? That’s the million-dollar question.

Shares traded as high as $5.85 October 6 on the news the Leafs by Snoops product would finally be available here in Canada. However, by the end of the day it had actually closed down nine cents from the previous day’s closing price of $4.98.

You know what they say: “Buy on rumour, sell on news.” And that’s exactly what investors did.

Interestingly, when Canopy first announced the partnership earlier in the year, its stock barely budged, trading in a tight range between $2.90 and $3.30 for over five months before trending higher in late July as a result of its move to the TSX big board. It then took its next leg up as word got out Snoop Dogg’s product would soon be available.

What needs to happen for Canopy stock to get to $10?

Earnings.

I know that seems academic, but that’s what drives the price of stocks. Real or potential future earnings and revenue growth are the only things that truly matter to investors.

So, how will Snoop Dogg’s brand presence here in Canada help move the needle?

Well, right now that’s pretty hard to quantify. The Leafs by Snoop brand is still less than a year old, having been launched last November. However, early results in Colorado suggest that Snoop Dogg’s products are popular with both fans and non-fans alike.

Emily Fata is a financial analyst specializing in the cannabis industry. She recently wrote about celebrity-branded cannabis businesses in a blog post for New Cannabis Ventures, an online website dedicated to the cannabis industry:

“When the brand had a limited release at LivWell dispensary in Denver, it was Snoop’s fans who showed up to purchase strains like Tangerine Dream and Cali Kush, as well as chocolate bars, cannabis drops, gummies, and peanut butter cups,” wrote Fata in her blog post. “Although Leaf by Snoop’s revenue has leveled out over the past several months, LivWell stated that the brand’s products have appealed to customers of all walks of life, ‘most particularly cannabis aficionados seeking high-end products and customers looking for unique experiences.’”

Fata goes on to discuss how celebrity-branded products like Leafs by Snoop are only marginally more expensive than non-celebrity-branded products, suggesting that as long as the rapper continues providing a quality product, there’s no reason that revenues south of the border won’t continue to grow as more states legalize both medical marijuana and recreational pot.

If you look at Canopy Growth’s sequential revenue growth for the last five quarters, it’s obvious that its business is growing quickly. Yes, it lost $3.9 million in the first quarter on revenue of $7 million, but when you’re growing by 40% on a sequential basis each quarter, the road to profitability isn’t far off.

How much revenue this partnership generates for Canopy Growth isn’t important, in my opinion. What is is the message it sends to cannabis users across the country.

And the message is?

Canopy Growth is the leading marijuana producer in this country. It’s serious about its business and has the wherewithal to bring partnerships like the one with Snoop Dogg to fruition.

It might not be enough to get Canopy Growth’s stock to $10 before the end of the year, but certainly, it’s going to help make that a reality in 2017.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Will Ashworth has no position in any stocks mentioned.

More on Investing

Index funds
Investing

Top 3 S&P 500 Index Funds

Here are my top three picks when it comes to investing in the S&P 500 for Canadians.

Read more »

calculate and analyze stock
Dividend Stocks

The 5 Best Low-Risk Investments for Canadians

If you're wanting to keep things low risk in this volatile market, these are the top five places where investors…

Read more »

Payday ringed on a calendar
Dividend Stocks

How to Build a Bulletproof Monthly Passive-Income Portfolio in 2024 With Just $25,000

Invest in quality monthly dividend ETFs such as the XDIV to create a recurring and reliable passive-income stream for life.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Friday, April 19

The main TSX index seems on track to post another losing week as it currently trades with 0.9% week-to-date losses.

Read more »

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Woman has an idea
Investing

3 No-Brainer Stocks to Buy With $200 Right Now

These three stocks are no-brainer buys, given their solid underlying businesses and healthy growth prospects.

Read more »

Investing

2 Stocks I’m Loading Up on in 2024

Alimentation Couche-Tard (TSX:ATD) and another stock that are getting too cheap after their latest corrections.

Read more »

grow money, wealth build
Dividend Stocks

1 Top Dividend Stock That Can Handle Any Kind of Market (Even Corrections)

While most dividend aristocrats can maintain their payouts during weak markets, very few can maintain a healthy valuation or bounce…

Read more »